EP1539805A4 - NUCLEIC ACIDS AND CORRESPONDING PROTEINS SAID 101P3A11 OR PHOR-1 FOR THE TREATMENT AND DETECTION OF CANCERS - Google Patents

NUCLEIC ACIDS AND CORRESPONDING PROTEINS SAID 101P3A11 OR PHOR-1 FOR THE TREATMENT AND DETECTION OF CANCERS

Info

Publication number
EP1539805A4
EP1539805A4 EP02736898A EP02736898A EP1539805A4 EP 1539805 A4 EP1539805 A4 EP 1539805A4 EP 02736898 A EP02736898 A EP 02736898A EP 02736898 A EP02736898 A EP 02736898A EP 1539805 A4 EP1539805 A4 EP 1539805A4
Authority
EP
European Patent Office
Prior art keywords
corresponsing
phor
cancer
useful
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02736898A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1539805A2 (en
Inventor
Aya Jakobovits
Mary Faris
Arthur B Raitano
Robert Kendall Morrison
Douglas Saffran
Wangmao Ge
Pia M Challita-Eid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/001,469 external-priority patent/US7208280B2/en
Priority claimed from US10/017,066 external-priority patent/US6838258B2/en
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of EP1539805A2 publication Critical patent/EP1539805A2/en
Publication of EP1539805A4 publication Critical patent/EP1539805A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02736898A 2001-05-15 2002-05-15 NUCLEIC ACIDS AND CORRESPONDING PROTEINS SAID 101P3A11 OR PHOR-1 FOR THE TREATMENT AND DETECTION OF CANCERS Withdrawn EP1539805A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17666 1979-03-05
US29111801P 2001-05-15 2001-05-15
US291118P 2001-05-15
US1469 2001-10-31
US10/001,469 US7208280B2 (en) 1999-10-05 2001-10-31 Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
US10/017,066 US6838258B2 (en) 1999-10-05 2001-12-14 G protein-coupled receptor up-regulated in prostate cancer and uses thereof
PCT/US2002/015520 WO2002092842A2 (en) 2001-05-15 2002-05-15 Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer

Publications (2)

Publication Number Publication Date
EP1539805A2 EP1539805A2 (en) 2005-06-15
EP1539805A4 true EP1539805A4 (en) 2005-11-16

Family

ID=38616826

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02736898A Withdrawn EP1539805A4 (en) 2001-05-15 2002-05-15 NUCLEIC ACIDS AND CORRESPONDING PROTEINS SAID 101P3A11 OR PHOR-1 FOR THE TREATMENT AND DETECTION OF CANCERS

Country Status (6)

Country Link
EP (1) EP1539805A4 (enExample)
JP (1) JP2005512509A (enExample)
AU (2) AU2002309873B2 (enExample)
CA (1) CA2447564A1 (enExample)
IL (1) IL158860A0 (enExample)
WO (1) WO2002092842A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US7208280B2 (en) 1999-10-05 2007-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
CA2517287C (en) * 2003-02-28 2022-12-13 The Johns Hopkins University Regulation of t cells by lag-3 (cd223)
JP5122592B2 (ja) * 2010-01-04 2013-01-16 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
US10722563B2 (en) * 2012-09-20 2020-07-28 Shenzhen Innovation Immunotechnology Co., Ltd. Prostate-specific tumor antigens and uses thereof
CN111549140B (zh) * 2020-06-08 2023-08-08 重庆医科大学附属第一医院 一种检测肺癌相关基因C2orf40、FIBIN和GRP甲基化的试剂盒及其应用
CN119920083B (zh) * 2025-01-21 2025-10-31 重庆邮电大学 一种通信中断条件下基于事件触发的混行车群切换协同控制方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033602A1 (en) * 1996-03-11 1997-09-18 Cytel Corporation Peptides with increased binding affinity for hla molecules
WO2000044775A2 (en) * 1999-01-27 2000-08-03 Epimmune Inc. Identification of broadly reactive hla restricted t cell epitopes
WO2001025434A1 (en) * 1999-10-05 2001-04-12 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
WO2001073032A2 (en) * 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001074904A2 (en) * 2000-03-31 2001-10-11 Curagen Corporation G-protein coupled receptors and nucleic acids encoding same
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2000020590A2 (en) * 1998-10-06 2000-04-13 Incyte Pharmaceuticals, Inc. G-protein coupled receptor proteins
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
AU2903701A (en) * 1999-10-08 2001-04-23 Digiscents Olfactory receptor sequences
US20030088059A1 (en) * 2000-03-13 2003-05-08 Sergey Zozulya Human olfactory receptors and genes encoding same
US20030022237A1 (en) * 2000-09-27 2003-01-30 Feder John N. Novel human G-protein coupled receptor, HGPRBMY4, expressed highly in prostate, colon, and lung
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033602A1 (en) * 1996-03-11 1997-09-18 Cytel Corporation Peptides with increased binding affinity for hla molecules
WO2000044775A2 (en) * 1999-01-27 2000-08-03 Epimmune Inc. Identification of broadly reactive hla restricted t cell epitopes
WO2001025434A1 (en) * 1999-10-05 2001-04-12 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
WO2001073032A2 (en) * 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001074904A2 (en) * 2000-03-31 2001-10-11 Curagen Corporation G-protein coupled receptors and nucleic acids encoding same
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 6 February 2003 (2003-02-06), "Prostate cancer marker protein", XP002345926, retrieved from EBI Database accession no. ADB75619 *

Also Published As

Publication number Publication date
AU2008200363A8 (en) 2008-03-13
AU2008200363B2 (en) 2010-08-12
WO2002092842A3 (en) 2005-04-21
EP1539805A2 (en) 2005-06-15
AU2008200363A1 (en) 2008-02-21
IL158860A0 (en) 2004-05-12
JP2005512509A (ja) 2005-05-12
WO2002092842A2 (en) 2002-11-21
AU2002309873B2 (en) 2007-10-18
CA2447564A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
EP1576130A4 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS NAMED 282P1G3 WITH FITNESS FOR THE TREATMENT AND DETECTION OF CANCER
AU2002318112B2 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1517606A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN CURED 193P1E1B USEFUL IN THE TREATMENT AND DETECTION OF CANCER
WO2003087306A8 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
AU2002337696A8 (en) Detection of tumor rna in plasma and serum
EP1622571A4 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS CURED 109P1D4 USEFUL IN THE TREATMENT AND DETECTION OF CANCER
PT1537140E (pt) Ácido nucleico e proteína correspondente designada 161p2f10b úteis no tratamento e detecção de cancro
EP1372719A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 125P5C8 FOR THE TREATMENT AND DETECTION OF CANCER
EP1590437A4 (en) NUCLEIC ACIDS SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER AND CORRESPONDING PROTEINS NAMED 254P1D6B
EP1539805A4 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS SAID 101P3A11 OR PHOR-1 FOR THE TREATMENT AND DETECTION OF CANCERS
AU2001285018A1 (en) Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
AU2002246708A1 (en) Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
WO2002083917A8 (en) Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
AU2001251621A1 (en) Gtp-binding protein useful in treatment and detection of cancer
GB0118995D0 (en) Detection of mutations in nucleic acids
EP1565200A4 (en) NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER
EP1399174A4 (en) NUCLEIC ACID AND RELATED PROTEIN, TREATABLE AND DETECTABLE FOR CANCER, NAME 121P1F1
EP1578980A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN 213P1F11 FOR USE IN THE TREATMENT AND DETECTION OF CANCER
HUP0303890A3 (en) Expression amalysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU2001286541A1 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer
AU2002306952A1 (en) Detection and treatment of colorectal cancer
IL155954A0 (en) Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU2002305171A1 (en) Nucleic acid sequences useful in the detection and treatment of various cancers
AU2002305170A1 (en) Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
IL164390A0 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20051004

17Q First examination report despatched

Effective date: 20070323

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGENSYS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110524